Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499471 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL303522 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL8496647 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL273088 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL8496345 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL8497072 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL302640 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL272185 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL303165 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 | |
| SCHEMBL302914 | 1.00 | SIGMAR1 (0.58) | SIGMAR1MAOAMAOBMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415474-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | UBE INDUSTRIES (JP) | 2013-08-28 | — | — | EP | claimed |
| EP-2221308-B1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES (JP) | 2013-07-10 | — | — | EP | claimed |
| US-8377922-B2 | Benzazepinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-02-19 | — | — | US | claimed |
| CN-102427816-A | Pharmaceutical composition for treating or preventing eye diseases | UBE INDUSTRIES | 2012-04-25 | — | — | CN | claimed |
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | UBE INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | claimed |
| EP-2415474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | claimed |
| CN-101861319-A | Benzazepinone compound | UBE INDUSTRIES | 2010-10-13 | — | — | CN | claimed |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2010-09-30 | — | — | US | claimed |
| EP-2221308-A1 | BENZAZEPINONE COMPOUND | Ube Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | claimed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | claimed |
| WO-2023176796-A1 | SCAR FORMATION INHIBITOR, FIBROBLAST PROLIFERATION INHIBITOR, AND METHOD FOR PRODUCING NANOPARTICLES | 国立大学法人東北大学 | 2023-09-21 | — | — | WO | disclosed |
| US-20230012337-A1 | POLYESTERS | CLARIANT INTERNATIONAL LTD. (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2021118814-A1 | A DETERGENT COMPOSITION COMPRISING A POLYMER | THE PROCTER & GAMBLE COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116049-A1 | POLYESTERS | CLARIANT INTERNATIONAL LTD (CH) | 2021-06-17 | — | — | WO | disclosed |
| EP-3835396-A1 | A DETERGENT COMPOSITION COMPRISING A POLYMER | The Procter & Gamble Company (US) | 2021-06-16 | — | — | EP | disclosed |
| US-4243609-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4190574-A | CHROMOPHORE- OR FLUORESCENT-SUBSTITUTED OLIGOPEPTIDE | PENTAPHARM A.G. (CH) | 1980-02-26 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4070245-A | Substrate for the quantitative determination of proteolytic enzymes | PENTAPHARM A.G. (CH) | 1978-01-24 | — | — | US | disclosed |
| US-4016042-A | SYNTHETIC OLIGOPEPTIDE CONTAINING A CHROMOGENIC OR FLUORESCENT GROUP SPLIT OFF BY PROTEOLYTIC ENZYMES | PENTAPHARM A.G. (CH) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | VEGFA, UACA, PGF | SIGMAR1 2362/4885MAOA 1590/4885MAOB 957/4885 |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | KCNJ11, KCNJ1, KCNJ2 | SIGMAR1 170/4885MAOA 730/4885MAOB 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.